

Meeting Notice

1. The 2024 shareholders' meeting will be convened at 9:00AM on June 21 (Friday), 2024 at No. 631 Zhongzheng Road Zhonghe District, New Taipei City (RSL Hotel Taipei Zhonghe) (shareholder sign-in time: 8:30AM; sign-in location: same place as the meeting).

Major contents of the meeting:

(1) Report Items:

1. 2023 business report and 2024 business plan.
2. Audit Committee's review report on the 2023 financial statements.
3. 2023 distribution report of employee compensation and director remuneration.
4. 2023 distribution report of cash dividends.
5. Amending part of the articles of the Company's "Regulations Governing Procedure for Board of Directors Meetings".

(2) Proposal Items:

1. Adoption of 2023 financial statements.
2. Adoption of 2023 earnings distribution.

(3) Discussion Items:

1. Issuing new shares for capital increase by earnings recapitalization.
2. Releasing the prohibition on directors from participation in competitive businesses.
3. Amending part of the articles of the Company's "Procedure for Election of the Directors".
4. Amending part of the articles of the Company's "Rules of Procedure for Shareholders Meetings".

(4) Extraordinary motion.

2. For the fiscal year 2023, the company has proposed a distribution plan for the retained earnings. The Board of Directors has determined to distribute a cash dividend of NT\$ 591,343,612 to shareholders for the year 2023, which amounts to NT\$ 3,800 per thousand shares. The Chairman is authorized to set the ex-dividend date for the distribution. Furthermore, it is proposed that the capital increase be made using retained earnings in the amount of NT\$77,808,370 which amounts to 50 shares per thousand shares. Once approved by the shareholders' meeting and reported to the regulatory authorities, the Board of Directors will authorize the Chairman to set the ex-rights date. In case of any change in the per-share cash dividend as a result of the fact that repurchase of the Company's shares, the treasury stock is transferred or deleted, or carries out a cash capital increase, which further affects the number of the Company's outstanding shares. The chairman shall be authorized to adjust the shareholder's cash dividend rate according to the distribution amount adopted for this proposal and the number of the Company's actual outstanding shares.
3. According to Article 209 of the Company Act, a director who acts for themselves or on behalf of others within the company's business scope shall explain to the Board of Shareholders the essential contents of such an act and obtain its approval. In case that any of the Company's directors invests in or operates a business same as or similar to the Company and acts as a director in such business, they shall submit the case to the shareholders' meeting and obtain its approval. If the Company's director is also under the aforesaid circumstance, the Company agrees to release the prohibition on directors from participation in competitive businesses, see the fifth couplet for more details.
4. According to Article 165 of the Company Act, the share ownership transfer shall be suspended from April 23, 2024 to June 21, 2024.

5. In addition to the announcement, we are enclosing a shareholder attendance registration card and a proxy form with this letter. We kindly request your presence at the meeting. If you plan to attend the meeting in person, please fill out the first copy of the attendance registration card and bring it with you to the venue on the day of the meeting. If you intend to appoint a proxy to attend on your behalf, please fill out the second copy of the proxy form along with the first copy of the attendance registration card and return them together. Please ensure that they are delivered to the Shareholder Services Department of our designated share registrar, Unified Securities Co., Ltd., no later than 5 days prior to the meeting. Once the information has been verified, the attendance registration card will be completed and sent back to your appointed proxy as a receipt for attending the shareholders' meeting. When shareholders, solicitors, appointed agents, and authorized representatives attend the shareholders' meeting, please bring the original identification document with a photo for verification. For the representative appointed by a legal entity, it is also necessary to submit an appointment letter with the official seal of the company..
6. The Company will produce a compiled list for the information of solicitors' solicitation before May 21, 2024 for those shareholders wishing to solicit letters of proxy and disclose it on the website of Securities & Futures Institutes at <http://free.sfi.org.tw>. Investors may directly visit the website, go to the "Free inquiry system for proxy letter announcement related information", click the "Enter the inquiry system for proxy letter announcement and meeting data" and fill in the inquiry terms to inquire the details.
7. For this shareholders' meeting, shareholders have the option to exercise their voting rights electronically. The exercise period is from May 22, 2024, to June 18, 2024. Please log in to the website of Taiwan Depository & Clearing Corporation's Shareholders' E-voting System, "StockVote" at <https://www.stockvote.com.tw>, and follow the provided instructions to cast your vote.
8. The designated verification institution for the proxy form of our company's shareholders' meeting is the Shareholder Services Department of Unified Securities Co., Ltd.
9. If there are matters that should be listed and explained in the convocation reasons under Article 172 of the Company Act, please visit the Taiwan Stock Exchange Market Observation Post System (MOPS) website at <http://emops.twse.com.tw/>. Follow the path: click on "Basic Information," then "Electronic Books," and select "Annual Reports and Shareholders' Meeting Related Information." Enter our company code "4104" and the fiscal year "113," then choose either "Reference Materials for Shareholders' Meeting Agenda" or "Meeting Handbook and Supplementary Materials" to access the relevant information.

Yours Sincerely

Board of Directors,
Excelsior Medical Co., Ltd.